Inovio Pharmaceuticals Inc (NYSEMKT:INO)’s shares jumped 2.20% to $3.30. The company on Mar. 26 announced that it was recognized with three industry awards at the World Vaccine Congress, which is being held this week in Washington, D.C. The Vaccine Industry Excellence (ViE) Awards recognize outstanding vaccine advancements and achievements of therapeutic and preventive vaccine developers across the global industry as judged by a panel of global biotech industry stakeholders. Inovio Pharmaceuticals Inc (NYSEMKT:INO) shares after opening at $3.34 moved to $3.45 on last trade day and at the end of the day closed at $3.23. Company price to sales ratio in past twelve months was calculated as 49.97 and price to cash ratio as 12.83. Inovio Pharmaceuticals Inc (NYSEMKT:INO) showed a positive/negative weekly performance of -15.45%.
Achillion Pharmaceuticals (NASDAQ:ACHN) was upgraded by investment analysts at Maxim Group from a “hold” rating to a “buy” rating in a note issued to investors on Monday, TheFlyOnTheWall.com reports. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) shares fell -7.30% in last trading session and ended the day on $3.43. ACHN return on equity ratio is recorded as -38.70% and its return on assets is -36.00%. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) yearly performance is -60.76%.
Synergy Pharmaceuticals (NASDAQ:SGYP) announced its earnings results reported ($0.22) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.20) by $0.02. During the same quarter last year, the company posted ($0.18) earnings per share. Synergy Pharmaceuticals Inc (NASDAQ:SGYP) shares moved down -8.03% in last trading session and was closed at $5.27 while trading in range of $5.22 – $5.88 – Synergy Pharmaceuticals Inc (NASDAQ:SGYP) year to date (YTD) performance is -5.05%.
Keryx Biopharmaceuticals (Nasdaq:KERX) up on report of a House “doc fix” proposal, which says ESRD oral drugs may not go into the bundle until 2024, from 2016. Keryx Biopharmaceuticals (NASDAQ:KERX) weekly performance is 8.60%. On last trading day company shares ended up $16.54. Keryx Biopharmaceuticals (NASDAQ:KERX) distance from 50-day simple moving average (SMA50) is 8.23%. Analysts mean target price for the company is $24.09.
Leave a Reply